6azm: Difference between revisions

← Older edit

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 3: / Line 3: @@
 <StructureSection load='6azm' size='340' side='right'caption='[[6azm]], [[Resolution|resolution]] 1.60&Aring;' scene=''>
 == Structural highlights ==
-<table><tr><td colspan='2'>[[6azm]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6AZM OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6AZM FirstGlance]. <br>
+<table><tr><td colspan='2'>[[6azm]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Plasmodium_falciparum Plasmodium falciparum]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6AZM OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6AZM FirstGlance]. <br>
-</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr>
+</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.6&#8491;</td></tr>
-<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6azm FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6azm OCA], [http://pdbe.org/6azm PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6azm RCSB], [http://www.ebi.ac.uk/pdbsum/6azm PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6azm ProSAT]</span></td></tr>
+<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr>
+<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6azm FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6azm OCA], [https://pdbe.org/6azm PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6azm RCSB], [https://www.ebi.ac.uk/pdbsum/6azm PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6azm ProSAT]</span></td></tr>
 </table>
-<div style="background-color:#fffaf0;">
+== Function ==
-== Publication Abstract from PubMed ==
+[https://www.uniprot.org/uniprot/CSP_PLAFA CSP_PLAFA] The circumsporozoite protein is the immunodominant surface antigen on the sporozoite (the infective stage of the malaria parasite that is transmitted from the mosquito to the vertebrate host).
-Antibodies against the NANP repeat of circumsporozoite protein (CSP), the major surface antigen of Plasmodium falciparum (Pf) sporozoites, can protect from malaria in animal models but protective humoral immunity is difficult to induce in humans. Here we cloned and characterized rare affinity-matured human NANP-reactive memory B cell antibodies elicited by natural Pf exposure that potently inhibited parasite transmission and development in vivo. We unveiled the molecular details of antibody binding to two distinct protective epitopes within the NANP repeat. NANP repeat recognition was largely mediated by germline encoded and immunoglobulin (Ig) heavy-chain complementarity determining region 3 (HCDR3) residues, whereas affinity maturation contributed predominantly to stabilizing the antigen-binding site conformation. Combined, our findings illustrate the power of exploring human anti-CSP antibody responses to develop tools for malaria control in the mammalian and the mosquito vector and provide a molecular basis for the structure-based design of next-generation CSP malaria vaccines.
-Natural Parasite Exposure Induces Protective Human Anti-Malarial Antibodies.,Triller G, Scally SW, Costa G, Pissarev M, Kreschel C, Bosch A, Marois E, Sack BK, Murugan R, Salman AM, Janse CJ, Khan SM, Kappe SHI, Adegnika AA, Mordmuller B, Levashina EA, Julien JP, Wardemann H Immunity. 2017 Dec 19;47(6):1197-1209.e10. doi: 10.1016/j.immuni.2017.11.007., Epub 2017 Nov 29. PMID:29195810<ref>PMID:29195810</ref>
-From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-</div>
-<div class="pdbe-citations 6azm" style="background-color:#fffaf0;"></div>
 ==See Also==
-*[[Antibody 3D structures|Antibody 3D structures]]
+*[[Monoclonal Antibodies 3D structures|Monoclonal Antibodies 3D structures]]
-== References ==
+*[[3D structures of human antibody|3D structures of human antibody]]
-<references/>
 __TOC__
 </StructureSection>
-[[Category: Human]]
+[[Category: Homo sapiens]]
 [[Category: Large Structures]]
-[[Category: Bosch, A]]
+[[Category: Plasmodium falciparum]]
-[[Category: Julien, J P]]
+[[Category: Bosch A]]
-[[Category: Scally, S W]]
+[[Category: Julien JP]]
-[[Category: Triller, G]]
+[[Category: Scally SW]]
-[[Category: Wardemann, H]]
+[[Category: Triller G]]
-[[Category: Circumsporozoite protein]]
+[[Category: Wardemann H]]
-[[Category: Fab]]
-[[Category: Immune system]]
-[[Category: Malaria]]